Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2017 by Spectrum Health Hospitals
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Giselle Sholler, Spectrum Health Hospitals
ClinicalTrials.gov Identifier:
NCT00601003
First received: January 14, 2008
Last updated: April 25, 2017
Last verified: April 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2020
  Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)